Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic.
about
Updates in hyperkalemia: Outcomes and therapeutic strategies.Mineralocorticoid Receptor Antagonism for Cardiovascular Protection in End-Stage Renal Disease: New Data But the Controversy Continues.Cirrhosis and its complications: evidence based treatment.Advances in treatment of hyperkalemia in chronic kidney disease.Hypokalemia, its contributing factors and renal outcomes in patients with chronic kidney disease.Randomized Clinical Trial of Sodium Polystyrene Sulfonate for the Treatment of Mild Hyperkalemia in CKDAssociation between Serum Potassium and Outcomes in Patients with Reduced Kidney Function.Potassium and Its Discontents: New Insight, New TreatmentsManagement of hyperkalaemia in chronic kidney disease.Red blood cell transfusion, hyperkalemia, and heart failure in advanced chronic kidney disease.How Dangerous Is Hyperkalemia?Pharmacodynamics and pharmacokinetics of sodium zirconium cyclosilicate [ZS-9] in the treatment of hyperkalemia.Potassium-Binding Agents to Facilitate Renin-Angiotensin-Aldosterone System Inhibitor Therapy.Recent advances in pharmacological treatments of hyperkalemia: focus on patiromer.New Agents in Treatment of Hyperkalemia: an Opportunity to Optimize Use of RAAS Inhibitors for Blood Pressure Control and Organ Protection in Patients with Chronic Kidney Disease.Nutrition in Renal Supportive Care: Patient-driven and flexible.Incidence of and risk factors for newly diagnosed hyperkalemia after hospital discharge in non-dialysis-dependent CKD patients treated with RAS inhibitors.Sodium zirconium cyclosilicate (ZS-9) for the treatment of hyperkalemia.Palatability and physical properties of potassium-binding resin RDX7675: comparison with sodium polystyrene sulfonateEvaluation of the Potential for Drug Interactions With Patiromer in Healthy Volunteers.The Unappreciated Role of Extrarenal and Gut Sensors in Modulating Renal Potassium Handling: Implications for Diagnosis of Dyskalemias and Interpreting Clinical Trials.Serum-to-dialysate potassium gradient and its association with short-term outcomes in hemodialysis patients.Evaluation of the Pharmacodynamic Effects of the Potassium Binder RDX7675 in Mice.Evaluation of the tolerability and efficacy of sodium polystyrene sulfonate for long-term management of hyperkalemia in patients with chronic kidney disease.Approaches to and Clinical Benefits of Reducing Dietary K in CKD.Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis.Impact of admission serum potassium on mortality in patients with chronic kidney disease and cardiovascular disease.
P2860
Q30245585-4CEE1D07-C024-46EB-91D5-F415506B5089Q31004378-8C2A553D-7351-4DB6-9222-0B2504D15083Q33594931-C144DC0B-BB23-4D89-AC58-C29A698147EBQ34491934-F363004C-3CA1-4CB1-99B7-B1901C290FD6Q34812460-3A4B0D6A-F3AC-4797-BEFE-9C26CBB8C3FDQ36349441-46235388-07DF-49D6-885D-3DAC5DF5F0D4Q36432845-B2B4D26F-E356-45C9-AD04-C78FCD913F16Q36746113-78CBA2FD-29BD-4575-8B52-40A14C5145CDQ38249892-AEAF5AED-EBA6-4A42-9E9A-93D65FDFD001Q38436060-71EB398E-E2EA-4574-AD47-10F89CE30C74Q38639874-E21176CA-91CD-4E0B-9911-75308750FD76Q38783092-3593E73A-5604-4C9C-B656-F40B43C072F5Q38786625-A7ADEEBE-7737-4D90-BFCB-5ACD48B8105FQ38834858-571DE562-D02E-4261-81B0-0E88FC031133Q38845433-4BD729F0-FDC6-49F3-81F3-E7A162B3B451Q39387617-946F8747-29FC-4EA3-B1C6-FAE9A9B194B5Q40055689-A91F2141-2D79-4ACD-BC44-1C185E34E4C7Q40753618-DB18E2B8-9B15-4157-9793-2949D56D1199Q41355707-96369A95-D82A-41D9-A83B-5D84E5099EBBQ41380691-73B838FF-9CEC-407B-A556-D46E3FA6F391Q43906046-A2BBC67F-4AE9-43A4-B9C8-22721757B092Q46125909-5845FB81-BE01-4D56-B2D0-9DCA6259ED05Q50051683-5C43AC4C-7D5D-42E9-832C-C57954AEE87CQ50063221-C6C5BA86-6238-4B8C-9135-E18CE18BAB36Q50146701-1BAEE38B-7D33-4B8A-BFEC-79BAD065447AQ52648659-C9316E93-3108-4CEC-9608-0DF7E8F9A396Q54070933-F7B8D915-A060-437B-8360-308F21ED121E
P2860
Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Prevalence and factors associa ...... wed in a low-clearance clinic.
@ast
Prevalence and factors associa ...... wed in a low-clearance clinic.
@en
type
label
Prevalence and factors associa ...... wed in a low-clearance clinic.
@ast
Prevalence and factors associa ...... wed in a low-clearance clinic.
@en
prefLabel
Prevalence and factors associa ...... wed in a low-clearance clinic.
@ast
Prevalence and factors associa ...... wed in a low-clearance clinic.
@en
P2093
P2860
P356
P1476
Prevalence and factors associa ...... owed in a low-clearance clinic
@en
P2093
Adam Rumjon
Aziza Al-Yassin
Eleri Wood
Jessica Fletcher-Rogers
Katie Vinen
Pantelis A Sarafidis
Rachel Ariyanayagam
Rochelle Blacklock
Shanique Simmonds
P2860
P304
P356
10.2215/CJN.01150112
P577
2012-05-17T00:00:00Z